Joseph Gilliam Sells 4,502 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) COO Joseph Gilliam sold 4,502 shares of the stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $124.65, for a total transaction of $561,174.30. Following the completion of the transaction, the chief operating officer directly owned 92,366 shares of the company’s stock, valued at $11,513,421.90. This trade represents a 4.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Glaukos Price Performance

NYSE GKOS traded down $5.94 during trading on Friday, reaching $119.96. 792,018 shares of the company traded hands, compared to its average volume of 709,591. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.47 and a current ratio of 5.20. The stock’s 50 day moving average price is $110.53 and its two-hundred day moving average price is $96.27. The company has a market cap of $6.89 billion, a price-to-earnings ratio of -77.89 and a beta of 0.67. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $161.78.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.11. The company had revenue of $133.54 million for the quarter, compared to the consensus estimate of $122.55 million. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The firm’s revenue for the quarter was up 38.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.28) EPS. As a group, analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current year.

Hedge Funds Weigh In On Glaukos

A number of hedge funds and other institutional investors have recently bought and sold shares of GKOS. AQR Capital Management LLC raised its position in shares of Glaukos by 2.6% during the 1st quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock valued at $766,000 after acquiring an additional 198 shares during the last quarter. Jones Financial Companies Lllp boosted its position in shares of Glaukos by 1,405.9% in the 1st quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock worth $252,000 after purchasing an additional 2,390 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Glaukos by 41.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock worth $22,636,000 after purchasing an additional 67,668 shares during the period. Assenagon Asset Management S.A. bought a new stake in Glaukos in the second quarter valued at about $1,245,000. Finally, GAMMA Investing LLC increased its holdings in Glaukos by 56.0% in the second quarter. GAMMA Investing LLC now owns 2,109 shares of the medical instruments supplier’s stock valued at $218,000 after purchasing an additional 757 shares during the last quarter. 99.04% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on GKOS. Piper Sandler reaffirmed an “overweight” rating and issued a $165.00 price target on shares of Glaukos in a report on Wednesday, January 14th. Needham & Company LLC restated a “buy” rating and issued a $125.00 price objective on shares of Glaukos in a research report on Wednesday, January 14th. Wells Fargo & Company upped their target price on shares of Glaukos from $120.00 to $122.00 and gave the stock an “overweight” rating in a research report on Thursday, October 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a report on Wednesday, October 8th. Finally, UBS Group boosted their price objective on shares of Glaukos from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, December 23rd. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $131.38.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.